- Home
- ENLT vs HRMY Comparison
ENLT vs HRMY Comparison
Compare ENLT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLT | HRMY |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 2.2B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ENLT | HRMY |
|---|---|---|
| Price | $45.56 | $38.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $37.50 | ★ $51.33 |
| AVG Volume (30 Days) | 31.7K | ★ 710.6K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.72 | 50.44 |
| EPS | 0.96 | ★ 3.17 |
| Revenue | $457,756,000.00 | ★ $825,944,000.00 |
| Revenue This Year | $355.90 | $23.11 |
| Revenue Next Year | $42.83 | $16.15 |
| P/E Ratio | $48.65 | ★ $12.15 |
| Revenue Growth | ★ 27.72 | 21.13 |
| 52 Week Low | $14.01 | $25.52 |
| 52 Week High | $45.82 | $40.93 |
Technical Indicators
Market Signals| Indicator | ENLT | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 73.31 | 59.90 |
| Support Level | $38.48 | $37.12 |
| Resistance Level | $40.03 | $39.60 |
| Average True Range (ATR) | 1.17 | 1.31 |
| MACD | 0.43 | -0.32 |
| Stochastic Oscillator | 99.16 | 36.53 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.